Diabetes and obesity
Wegovy reduced BMI in children ages 6 to 11 in trial
In a trial, children ages 6 to 11 taking Wegovy had a 13.5% mean BMI decrease at week 68, compared with a 2.7% increase with placebo.

The phase III STEP Young trial found that semaglutide, sold as Wegovy, reduced BMI in children ages 6 to 11 with obesity. At week 68, mean BMI decreased by 13.5% with semaglutide and increased by 2.7% with placebo, according to MedPage Today. The trial included 167 children, and both groups received lifestyle counseling.
By week 104, mean BMI change was -9.4% with semaglutide and +8.4% with placebo, MedPage Today reported. Gastrointestinal side effects were most common. Through week 111, vomiting occurred in 70% of children receiving semaglutide and 29% receiving placebo, while diarrhea occurred in 62% and 35%, respectively. Serious adverse events occurred in 9% of each group.
Wegovy is approved for adolescents with obesity ages 12 and older, but not for children under 12, according to the reports. MedPage Today reported that Novo Nordisk has not announced plans to submit the trial data to the FDA.


